Axel M. Hillmer

University of Cologne — Germany

Biochemistry, Genetics and Molecular Biology · Life Sciences

52h-index12.6kcitations212works2.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Genomics and Diagnostics(55), Lung Cancer Treatments and Mutations(43), Hair Growth and Disorders(32), RNA modifications and cancer(20), Computational Drug Discovery Methods(15)

Publications209 total

Single-cell insights into tumor microenvironment heterogeneity and plasticity: transforming precision therapy in gastrointestinal cancers
Journal of Experimental & Clinical Cancer Research·2025· 2 citedOpen Access
Supplementary Information from Common Germline Risk Variants Impact Somatic Alterations and Clinical Features across Cancers
2025Open Access
Single-cell analysis of Barrett’s esophagus and carcinoma reveals cell types conferring risk via genetic predisposition
Cell Genomics·2025· 1 citedOpen Access
Basal-like subtype of esophageal adenocarcinoma and it’s morphological, molecular and clinical characteristics
Scientific Reports·2025· 1 citedOpen Access
AKR1C3 enhances radioresistance in esophageal adenocarcinoma via inhibiting ferroptosis through suppressing TRIM21-mediated ubiquitination of HSPA5
Cell Death and Disease·2025· 5 citedOpen Access
Olfactory receptor 2 drives abdominal aortic aneurysm by promoting CX3CR1-mediated monocyte recruitment
2025Open Access
Esophageal adenocarcinoma relapse after chemoradiation is dominated by a basal-like subtype
2025Open Access
Gene expression adaptation of metastases to their host tissue
2024Open Access
Single cell analysis of Barrett’s esophagus and carcinoma reveals cell types conferring risk via genetic predisposition
2024· 1 citedOpen Access
Benchmark of screening markers for KEAP1/NFE2L2 mutations and joint analysis with the K1N2-score
npj Precision Oncology·2024Open Access
Tumor architecture and emergence of strong genetic alterations are bottlenecks for clonal evolution in primary prostate cancer
Cell Systems·2024· 1 citedOpen Access
Addition of Durvalumab to neoadjuvant chemoradiotherapy (CROSS) in esophageal adenocarcinoma – first results from the prospective Phase-II RICE trial
Zeitschrift für Gastroenterologie·2024
Integrative genomic analyses of European intrahepatic cholangiocarcinoma: Novel <i>ROS1</i> fusion gene and PBX1 as prognostic marker
Clinical and Translational Medicine·2024· 4 citedOpen Access
Tumor phylogeography reveals block-shaped spatial heterogeneity and the mode of evolution in Hepatocellular Carcinoma
Nature Communications·2024· 16 citedOpen Access
Germline homozygosity and allelic imbalance of HLA-I are common in esophagogastric adenocarcinoma and impair the repertoire of immunogenic peptides
Journal for ImmunoTherapy of Cancer·2024· 5 citedOpen Access
Development, testing and validation of a targeted NGS-panel for the detection of actionable mutations in lung cancer (NSCLC) using anchored multiplex PCR technology in a multicentric setting
Pathology & Oncology Research·2024· 5 citedOpen Access
Frequency and functional characterization of fusion genes in squamous cell carcinoma of the lung
Gene·2023· 3 cited
In Response
Journal of Thoracic Oncology·2023Open Access
1521P Addition of durvalumab to CROSS in oesophageal adenocarcinoma is feasible and safe
Annals of Oncology·2023Open Access
1431P The nNGM Preclinical Platform: Preclinical research to generate evidence for patients with non-small cell lung cancer harboring variants of unknown significance
Annals of Oncology·2023
page 1 of 11Next →

Frequent Co-authors

Markus M. Nöthen(19), Sven Cichon(11), Roland Kruse(10), Audrey S.M. Teo(9), Patrick Tan(8), Regina C. Betz(8), S. Hanneken(8), Wan‐Teck Lim(7), Yijun Ruan(7), Wing‐Kin Sung(7), Tim Becker(7), Sibylle Eigelshoven(7), Angela Takano(6), Niranjan Nagarajan(6), Pramila Ariyaratne(6), Xing Yi Woo(6), Xiaoan Ruan(6), Elaine Guo Yan Chew(6), Peter Propping(6), Yee Yen Sia(6)